News

Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing novel Superkines for oncology and ...
University of Toronto14d
Combination therapy shows improved health outcomes for teens with type 1 diabetes: Study
Combining insulin treatment with the investigational drug dapagliflozin may improve health outcomes for adolescents with type 1 diabetes, according to a clinical trial led by endocrinologist Farid ...